Dan Marquess Net Worth

Dan Marquess biography

Dr. Dan Marquess serves as Chief Scientific Officer of the Company. Prior to that, Dr. Marquess held roles of increasing responsibility at Theravance Biopharma, Inc., a public biopharmaceutical company, from June 1998 to December 2015, including as Vice President and Head of Medicinal Chemistry, and at GlaxoSmithKline, plc, a public pharmaceutical company from 1994 to 1998, including as a research scientist. Since November 2011, he has served as pharmaceutical discovery advisor to the Wellcome Trust, the second largest biomedical charitable organization in the world. Dr. Marquess received a B.S. in Chemistry from the Queen’s University, Belfast, Northern Ireland, and a D. Phil in Organic Chemistry from the University of Oxford.

How old is Dan Marquess?

Dan Marquess is 51, he's been the Chief Scientific Officer of Unity Biotechnology Inc since 2015. There are 17 older and 4 younger executives at Unity Biotechnology Inc. The oldest executive at Unity Biotechnology Inc is David Lacey, 67, who is the Independent Director.

What's Dan Marquess's mailing address?

Dan's mailing address filed with the SEC is C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Unity Biotechnology Inc

Over the last 7 years, insiders at Unity Biotechnology Inc have traded over $9,012,473 worth of Unity Biotechnology Inc stock and bought 3,200 units worth $28,480 . The most active insiders traders include Kristina Burow, Robert Nelsen y Nathaniel E David. On average, Unity Biotechnology Inc executives and independent directors trade stock every 54 days with the average trade being worth of $65,316. The most recent stock trade was executed by Alexander Hieu Nguyen on 2 August 2024, trading 154 units of UBX stock currently worth $236.

What does Unity Biotechnology Inc do?

unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.

Unity Biotechnology Inc executives and stock owners

Unity Biotechnology Inc executives and other stock owners filed with the SEC include:

• Keith Leonard,
  Chairman of the Board
• Margo Roberts,
  Independent Director
• Nathaniel David,
  President, Co-Founder, Director
• Dr. Anirvan Ghosh,
  CEO & Director
• Dr. Jamie Dananberg M.D.,
  Chief Medical Officer
• Dr. Jamie Dananberg,
  Chief Medical Officer
• Lynne Marie Sullivan,
  CFO & Head of Corp. Devel.
• Paul Berns,
  Independent Director
• Graham Cooper,
  Independent Director
• David Lacey,
  Independent Director
• Kristina Burow,
  Independent Director
• Camille Samuels,
  Independent Director
• Robert Nelsen,
  Director
• Dr. Nathaniel E. David A.B., Ph.D.,
  Co-Founder & Exec. Director
• Luis Visoso,
  Director
• Mary Campbell,
  Director
• Jamie Dananberg,
  Chief Medical Officer
• Tamara Tompkins,
  General Counsel and Corporate Secretary
• Dan Marquess,
  Chief Scientific Officer
• Lynne Sullivan,
  Chief Financial Officer, Chief Accounting Officer
• Anirvan Ghosh,
  Chief Executive Officer, Director
• Dr. Nathaniel E. David,
  Co-Founder & Exec. Director
• Susan Lundeen Smuck,
  Chief HR Officer
• Dr. Przemyslaw Sapieha Ph.D.,
  Chief Scientific Advisor
• Alexander Azoy,
  VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer
• Nathan Guz Ph.D.,
  VP of Operations
• Daohong Zhou M.D.,
  Founder
• Dr. Judith Campisi,
  Founder
• Dr. Jan M. van Deursen,
  Founder
• Alexander Azoy,
  See Remarks
• Alexander Hieu Nguyen,
  Chief Legal Officer
• Ii Robert C. Goeltz,
  Chief Financial Officer
• Venture Partners Vii, Llcar...,
  
• Michael P. Samar,
  
• Gilmore Neil O'neill,